Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, United States.
Departments of Cardiovascular Diseases and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, United States.
Am J Physiol Gastrointest Liver Physiol. 2024 May 1;326(5):G495-G503. doi: 10.1152/ajpgi.00263.2023. Epub 2024 Mar 12.
Tissue-specific gene manipulations are widely used in genetically engineered mouse models. A single recombinase system, such as the one using Alb-Cre, has been commonly used for liver-specific genetic manipulations. However, most diseases are complex, involving multiple genetic changes and various cell types. A dual recombinase system is required for conditionally modifying different genes sequentially in the same cell or inducing genetic changes in different cell types within the same organism. A FlpO cDNA was inserted between the last exon and 3'-UTR of the mouse albumin gene in a bacterial artificial chromosome (BAC-Alb-FlpO). The founders were crossed with various reporter mice to examine the efficiency of recombination. Liver cancer tumorigenesis was investigated by crossing the FlpO mice with FSF-Kras mice and p53 mice (KPF mice). BAC-Alb-FlpO mice exhibited highly efficient recombination capability in both hepatocytes and intrahepatic cholangiocytes. No recombination was observed in the duodenum and pancreatic cells. BAC-Alb-FlpO-mediated liver-specific expression of mutant Kras and conditional deletion of gene caused the development of liver cancer. Remarkably, liver cancer in these KPF mice manifested a distinctive mixed hepatocellular carcinoma and cholangiocarcinoma phenotype. A highly efficient and liver-specific BAC-Alb-FlpO mouse model was developed. In combination with other Cre lines, different genes can be manipulated sequentially in the same cell, or distinct genetic changes can be induced in different cell types of the same organism. A liver-specific Alb-FlpO mouse line was generated. By coupling it with other existing CreERT or Cre lines, the dual recombinase approach can enable sequential gene modifications within the same cell or across various cell types in an organism for liver research through temporal and spatial gene manipulations.
组织特异性基因操作广泛应用于基因工程小鼠模型。单一的重组酶系统,如 Alb-Cre 系统,常用于肝脏特异性基因操作。然而,大多数疾病是复杂的,涉及多个基因变化和多种细胞类型。为了在同一细胞中顺序修饰不同的基因,或者在同一生物体中诱导不同细胞类型的遗传变化,需要使用双重组酶系统。在细菌人工染色体(BAC-Alb-FlpO)中,FlpO cDNA 被插入到小鼠白蛋白基因的最后一个外显子和 3'UTR 之间。通过与各种报告小鼠杂交,研究了重组的效率。通过将 FlpO 小鼠与 FSF-Kras 小鼠和 p53 小鼠(KPF 小鼠)杂交,研究了肝癌肿瘤发生。BAC-Alb-FlpO 小鼠在肝细胞和肝内胆管细胞中表现出高效的重组能力。在十二指肠和胰腺细胞中未观察到重组。BAC-Alb-FlpO 介导的突变 Kras 的肝脏特异性表达和 基因的条件性缺失导致了肝癌的发生。值得注意的是,这些 KPF 小鼠的肝癌表现出独特的混合肝细胞癌和胆管癌表型。开发了一种高效的肝脏特异性 BAC-Alb-FlpO 小鼠模型。与其他 Cre 线结合,不同的基因可以在同一细胞中顺序操作,或者可以在同一生物体的不同细胞类型中诱导不同的遗传变化。生成了一种肝脏特异性 Alb-FlpO 小鼠系。通过与其他现有的 CreERT 或 Cre 线结合,双重组酶方法可以通过时空基因操作,在同一细胞或生物体中的各种细胞类型中进行基因的顺序修饰。